New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial

NCT ID NCT04508790

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding leflunomide to the standard drugs pomalidomide and dexamethasone can better control multiple myeloma that has come back or is resistant to treatment. About 29 adults with relapsed or refractory myeloma will receive the three-drug combination. The goal is to see if the new mix improves response rates while keeping side effects manageable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PLASMA CELL MYELOMA REFRACTORY PLASMA CELL MYELOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
City of Hope at Antelope Valley
RECRUITING

Lancaster, California, 93534, United States
City of Hope at Long Beach Elm
RECRUITING

Long Beach, California, 90813, United States
City of Hope at Newport Beach Fashion Island
RECRUITING

Newport Beach, California, 92660, United States
City of Hope at Seacliff
RECRUITING

Huntington Beach, California, 92648, United States
City of Hope at South Bay
RECRUITING

Torrance, California, 90503, United States
City of Hope at South Pasadena
RECRUITING

South Pasadena, California, 91030, United States
City of Hope at Upland
RECRUITING

Upland, California, 91786, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.